#USA #SK Life Science #Paramus #XCOPRI #Access+

SK Life Science Introduces Access+

On November 1, 2026, SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., unveiled Access+, a groundbreaking initiative aimed at enhancing the journey for patients and healthcare providers navigating the need for prescriptions and treatments. This innovative offering seeks to simplify the often-complex process between obtaining a prescription and receiving treatment, particularly for the antiseizure medication XCOPRI® (cenobamate tablets) CV.

What is Access+?

Access+ is an integrated platform that merges crucial services like pharmacy offerings, home delivery, and support from SK Life Science’s Patient Assistance Program (PAP). This holistic approach allows for a more user-friendly experience for patients who have been prescribed XCOPRI, which is used to manage partial-onset seizures in adults. The launch of Access+ represents SK Life Science's commitment to improving not just treatment options but the overall patient experience.

Key Features of Access+

One of the central components of Access+ is the SK Life Science Access+ Pharmacy. This is a centralized, non-dispensing pharmacy pathway that provides benefits verification and support services before routing prescriptions for fulfillment. Healthcare providers can electronically prescribe XCOPRI directly to the Access+ Pharmacy, ensuring a smooth transition from prescription to treatment.

For patients, this means that the intake process can be managed through home delivery options and streamlined services tailored to their specific insurance plans, including commercial insurance, Medicare, and Medicaid. This comprehensive access supports patients regardless of their coverage situation, thereby promoting health equity.

A Simplified Enrollment Process

As part of the enhancements, Access+ simplifies enrollment in the Patient Assistance Program by removing the need for traditional forms. Instead, healthcare providers can use the electronic prescriptions as the enrollment form, allowing the eligibility to be confirmed swiftly through a phone-based process. This paradigm shift not only eases the administrative barriers but also fosters a proactive approach to patient care.

Leadership Insights

Kristina G. Stracco, the Vice President of Market Access, Trade, and Patient Services at SK Life Science, emphasized, "Our commitment to the epilepsy community extends beyond advancing treatments to improving navigation to prescribed therapy. Access+ provides a reliable, convenient option to alleviate the burden on both patients and providers." Meanwhile, CEO Donghoon Lee remarked on the broader implications of innovation in neuroscience, stating that the development of user-friendly tools is as critical as discovering new treatments.

Navigating the Path to Treatment

Through Access+, patients can provide essential consent and fill out their information during the prescription intake phase. This proactive engagement allows for the assessment of needs and the initiation of applicable support services before prescriptions are dispensed. With the promise of home delivery, patients can receive their medications in a manner that is both convenient and efficient.

The Access+ program also supports eligible patients through the Patient Assistance Program, which is crucial for those who might face financial challenges in accessing their medication. The support provided through Access+ is structured to make the path to treatment less daunting, fostering a smoother healthcare experience.

Conclusion

SK Life Science Access+ not only retains the beneficial programs previously offered through SK Life Science Navigator but further expands on them, aiming to create a truly integrated care solution. For patients and healthcare providers, this innovation serves as a vital tool in the ongoing journey of managing epilepsy and ensuring that prescribed medications, like XCOPRI, are accessible and manageable.

For more information about Access+ and available services, visit www.sklsaccess.com.